SIREN : 529210494
CSMED is a French company founded 15 years ago, specialized in the sector Ingénierie, études techniques. Based in BEZIERS (34500), this company of category GE shows in 2024 a revenue of 2.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 655 362 € | 2 944 256 € | 2 056 352 € | 1 351 819 € | 1 064 329 € | 1 023 965 € | 934 768 € | N/C | N/C |
| Net income | -472 631 € | -120 121 € | -486 744 € | 85 789 € | -1 794 246 € | -98 889 € | 35 784 € | -77 292 € | -15 572 € |
| EBITDA | 1 704 306 € | 2 211 418 € | 1 380 261 € | 1 031 670 € | 407 729 € | 810 305 € | 732 871 € | -68 891 € | -15 195 € |
| Net margin | -17.8% | -4.1% | -23.7% | 6.3% | -168.6% | -9.7% | 3.8% | N/C | N/C |
In 2024, CSMED achieves revenue of 2.7 M€. Over the period 2018-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +19.0%. Slight decline of -10% vs 2023. After deducting consumption (0 €), gross margin stands at 2.7 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.7 M€, representing 64.2% of revenue. Warning negative scissor effect: despite revenue change (-10%), EBITDA varies by -23%, reducing margin by 10.9 pts. This reflects costs rising faster than revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Net income is negative at -473 k€ (-17.8% of revenue), which will impact equity.
2 655 362 €
2 655 362 €
1 704 306 €
-187 811 €
-472 631 €
64.2%
The debt ratio (= Financial debt / Equity x 100) stands at 396%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 19%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 16.1 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 53.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
396.102%
19.301%
53.519%
16.114
76.3%
In 2024, the debt ratio of CSMED (396.10) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of CSMED (19.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of CSMED (16.11) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 39.69. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 28.2x. Operating income very largely covers interest expenses: high safety margin.
39.688
28.24
In 2024, the liquidity ratio of CSMED (39.69) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of CSMED (28.2x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 37 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 288 days. Excellent situation: suppliers finance 251 days of the operating cycle (retail model). WCR is negative (-27 days): operations structurally generate cash.
-196 258 €
37 j
288 j
0 j
-27 j
Indicative estimate only : the number of comparable transactions in this sector is limited (40 transactions). This range of 446 233€ to 4 816 283€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 40 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare CSMED with other companies in the same sector:
Voir toutes les statistiques du secteur Ingénierie, études techniques
The revenue of CSMED in 2024 is 2.7 M€.
CSMED recorded a net loss in 2024.
The headquarters of CSMED is located in BEZIERS (34500), in the department Herault.
The tax return of CSMED is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
CSMED operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.